No unexpected reactions present among mRNA COVID-19 vaccination in kids
The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).
What's going on with polio, monkeypox, and COVID-19
The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?
Antiviral treatment for hospitalized influenza pediatric patients declining
From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.
What Omicron could mean for the pandemic
Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.
FDA clears investigational NDA for VAX-31 to prevent invasive pneumococcal disease
The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.
MenACWY program associated with reduced invasive meningococcal disease among adolescents
The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.
